SOLICITATION NOTICE
H -- Analysis of PGE-M levels using liquid chromatography/tandem mass spectrometric method
- Notice Date
- 8/6/2007
- Notice Type
- Solicitation Notice
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- Reference-Number-NCI-70106-NV
- Response Due
- 8/20/2007
- Archive Date
- 9/4/2007
- Description
- In accordance with simplified acquisition procedures the National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), Occupational and Environmental Epidemiology Branch (OEEB) plans to procure on a sole source basis with Vanderbilt University, School of Medicine, 536 Robinson Research Building, Nashville, TN 37232 to perform analysis of PGE-M levels using liquid chromatography/tandem mass spectrometric method in 340 spot urine samples from the Shanghai Women?s Health Study. A reduced risk of stomach cancer has been associated with the use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) in numerous epidemiologic studies. The chemopreventive effects of NSAIDs are thought to be largely mediated through their roles in the inhibition of cyclooxygenase-2 (COX-2) and prostaglandin (PG) production. COX-2 plays a key role in diverse inflammatory conditions. Of the PGs, PGE2 is a major prostanoid in gastric tissue and involved in various physiological and pathological functions of gastric mucosal cells. It plays a critical role in maintenance of gastric mucosal integrity via several mechanisms including regulation of gastric mucosal blood flow, kinetics of epithelial cells, synthesis of mucus, and inhibition of gastric acid secretion. It has been shown that gastric cancer tissues release higher levels of PGE2 than non-neoplastic mucosa, and gastric mucosal PGE2 production is higher in H. pylori positive gastric cancer patients than in H. pylori-negative patients. Dr. Jason Morrow?s lab at the Vanderbilt University developed and validated an accurate and precise method to quantify PGE2 production in humans by measuring the major urinary metabolite of PGE2 (PGE-M, 11 alpha-hydroxy-9,15-dioxo-2,3,4,5-tetranor-prostane-1,20-dioic acid). Subsequently, urinary PGE-M levels have been significantly associated with increasing risk of colorectal cancer in a dose-response manner in the Shanghai Women?s Health Study. Similar to stomach cancer, a reduced risk of colorectal cancer has also been associated with the use of aspirin and other NSAIDs in numerous epidemiologic studies. These findings suggest that PGE2 plays a role in gastric carcinogenesis, and that urinary PGEM levels may also predict stomach cancer risk. However, to date, no study has evaluated the relation between urinary PGEM levels and stomach cancer risk. The laboratory of Dr. Marrow at Vanderbilt University will perform the highly sensitive and accurate liquid chromatography/tandem mass spectrometric method for measuring PGE-M levels on 340 spot urine samples. No other laboratory has acquired the expertise in testing urinary PGE-M levels in human. This method has been applied in a colorectal cancer case-control study nested within the Shanghai Women?s Health Study, and results have been published in the prestigious Journal of Clinical Oncology. The proposed stomach cancer analysis is also nested within the Shanghai Women?s Health Study. To facilitate evaluation of quality control and interpretation of results, it is important that the stomach cancer study have the same laboratory conduct the PGEM analysis. Vanderbilt University is the only vendor known to the OEEB that can process these samples without the introduction of new variables into ongoing research. This is not a solicitation for competitive quotations. However, if any interested party believes it can provide the above service, without introducing new variables into an ongoing research experiments it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. An original and one copy of the capability statements must be received in the contracting office by 1:00 p.m. EDT, on August 20, 2007. Faxed and emailed capability statements are NOT authorized. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to dm170b@nih.gov. It is the vendor's responsibility to call (301) 402-4509 to verify questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award from the NCI contractors must be registered in the Online Representations and Certifications Applications (ORCA). Please refer to http://orca.bpn.gov in order to register. In addition, contractors must be registered in the Central Contractor Registration (CCR) www.ccr.gov. No collect calls will be accepted. NAICS 541380. Size Standard $11M.
- Record
- SN01363051-W 20070808/070806220440 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |